Three‐Year Outcomes of Cranial Nerve Stimulation for Obstructive Sleep Apnea

Woodson, B. Tucker; Soose, Ryan J.; Gillespie, M. Boyd; Strohl, Kingman P.; Maurer, Joachim T.; Vries, Nico de; Steward, David L.; Baskin, Jonathan Z.; Badr, M. Safwan; Lin, Ho Sheng; Padhya, Tapan; Mickelson, Sam; Anderson, William; Vanderveken, Olivier M.; Strollo, Patrick J.

doi:10.1177/0194599815616618

Cited by 212 publications

(214 citation statements)

References 23 publications

Supporting

Mentioning

203

Contrasting

Unclassified

Order By: Relevance

“…Additional studies of the STAR cohort showed maintenance of these outcomes at 18, 24, and 36 months. [6][7][8][9] Two case series with chart reviews have been published since, with smaller cohorts of patients that have been consistent with the results seen in the STAR trials. Kent et al 10 reviewed their series of 20 patients and found improvement in postoperative AHI and ESS from 33.3 to 5.1 and 10.3 to 6 respectively.…”

Section: Discussionsupporting

confidence: 55%

Upper Airway Stimulation for Treatment of Obstructive Sleep Apnea: An Evaluation and Comparison of Outcomes at Two Academic Centers

Huntley

Kaffenberger

Doghramji

et al. 2017

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

undergoing upper airway stimulation (UAS) were analyzed. We hypothesize that treatment with UAS will improve both subjective and objective outcome measures and results will be reproducible between institutions. Methods: We reviewed patients undergoing UAS between May 2014 and August 2016. We recorded demographic data, Epworth Sleepiness Scale (ESS), and preoperative and postoperative polysomnographic information. We compared outcome data between institutions and subsequently combined the cohorts and compared baseline to posttreatment results. Results: The TJUH cohort consisted of 30 males and 18 females with a mean age of 60.88 years and body mass index of 29.29. The mean preoperative apnea-hypopnea index (AHI), O2 nadir, and ESS were 35.88, 80.96, and 11.09, respectively. The mean postoperative AHI, O2 nadir, and ESS were 6.34, 88.04, and 5.77, respectively. The UPMC cohort consisted of 30 males and 19 females with a mean age of 62.84 years and body mass index of 27.74. The mean preoperative AHI, O2 nadir, and ESS were 35.29, 79.58, and 10.94, respectively. The mean postoperative AHI, O2 nadir, and ESS were 6.28, 84.35, and 6.60, respectively. We found no difference in patients reaching a postoperative AHI less than 15, 10, and 5 when comparing the cohorts. After combining cohorts, we found a significant improvement in postoperative AHI, O2 nadir, and ESS compared to preoperative values. Conclusions: UAS appears to provide a viable alternative to continuous positive airway pressure, producing improvement in both polysomnographic and quality-of-life measures. Results are reproducible at high-volume centers.

show abstract

Section: Discussionsupporting

confidence: 55%

Upper Airway Stimulation for Treatment of Obstructive Sleep Apnea: An Evaluation and Comparison of Outcomes at Two Academic Centers

Huntley

Kaffenberger

Doghramji

et al. 2017

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

show abstract

“…43,44 Hypoglossal nerve stimulation reduces the AHI by 68%, from 29.3 events to 9 events per hour, 43 with sustained benefit at 3-year follow-up. 44 Participants with a BMI of .32 kg/m 2 and those with concentric retropalatal collapse on drug-induced sleep endoscopy are not candidates for hypoglossal nerve stimulation. 43 Hypoglossal nerve stimulation: Consider for patients with BMI ,32 kg/m 2 ; drug-induced sleep endoscopy is required to determine the patient's candidacy; concentric retropalatal collapse is a contraindication.…”

Section: What Surgical Osa Treatment Targets Neuromuscular Tone?mentioning

confidence: 99%

“…43,44 When turned on, the device stimulates the hypoglossal nerve and protrudes the tongue, opening the pharyngeal airway and maintaining patency. 43,44 Hypoglossal nerve stimulation reduces the AHI by 68%, from 29.3 events to 9 events per hour, 43 with sustained benefit at 3-year follow-up. 44 Participants with a BMI of .32 kg/m 2 and those with concentric retropalatal collapse on drug-induced sleep endoscopy are not candidates for hypoglossal nerve stimulation.…”

Section: What Surgical Osa Treatment Targets Neuromuscular Tone?mentioning

confidence: 99%

Treatment options for obstructive sleep apnea

Pavwoski

Shelgikar

2017

Neur Clin Pract

View full text Add to dashboard Cite

Purpose of review:Obstructive sleep apnea (OSA) is a global problem with implications for general health and quality of life, and is often encountered in patients with neurologic disease. This review outlines treatment modalities to consider for management of OSA in patients with neurologic disease.Recent findings:New advances in positive airway pressure (PAP) devices, oral appliances, and surgical interventions offer a wide range of treatment options for patients with OSA.Summary:PAP therapy remains the gold standard treatment for OSA. Other treatment modalities may be considered for OSA patients who decline or cannot tolerate PAP therapy. Some OSA patients may benefit from multimodal treatment.

show abstract

“…The study outcomes have shown that improvements observed at one-year were sustained at the three-year follow-up mark. These include 78% reduction in AHI events, 80% reduction in oxygen desaturation events, high adherence to therapy and improvements in quality of life 94 . The other procedures including distraction osteogenesis, rapid maxillary expansion, and laser midline glossectomy, lingual plasty, nasal surgery (septoplasty, turbinectomy, and polypectomy) may be useful as adjuncts to above mentioned measures.…”

Section: Surgical Interventionsmentioning

confidence: 99%

Obstructive Sleep Apnoea: A Risk Factor for Hypertension

Bader¹

2018

J Cardiol and Cardiovasc Sciences

View full text Add to dashboard Cite

Obstructive Sleep Apnoea (OSA) is the most prevalent condition among sleep disordered breathing that leads to increased risk of cardiovascular (CV) and cerebrovascular morbidity and mortality. The most common comorbidity associated with OSA is systemic hypertension (HTN). Various epidemiological studies suggest a link between OSA and hypertension that involves complex interactions between various pathophysiological mechanisms and metabolic risk factors. OSA causes changes in normal physiological functions during nocturnal apneic episodes which in-turn lead to daytime hypertension. The widely accepted mechanisms by which the OSA contributes to the development of hypertension include sympathetic activation, inflammation, oxidative stress, and endothelial dysfunction. OSA and hypertension coexist in millions of people and both have been associated with heart disease, stroke, and premature death. Worldwide the prevalence of hypertension in OSA is estimated between 30 and 70%, thus setting it off as a major public health problem. Furthermore, not only has OSA been implicated in causing new hypertension but also it is said to promote resistant hypertension in already existent hypertensive patients, which may further grim the clinical and therapeutic outcomes. It is necessary to recognize the underlying OSA in-order to decrease the overall healthcare burden in terms of rigorous antihypertensive therapy instituted to OSA subjects. The review summarizes an up-to-date scenario of obstructive sleep apnoea as a cause of systemic hypertension and the overall cardiovascular risks.

show abstract

Three‐Year Outcomes of Cranial Nerve Stimulation for Obstructive Sleep Apnea

Abstract: Long-term 3-year improvements in objective respiratory and subjective quality-of-life outcome measures are maintained. Adverse events are uncommon. UAS is a successful and appropriate long-term treatment for individuals with moderate to severe OSA.

Cited by 212 publications

References 23 publications

Upper Airway Stimulation for Treatment of Obstructive Sleep Apnea: An Evaluation and Comparison of Outcomes at Two Academic Centers

Upper Airway Stimulation for Treatment of Obstructive Sleep Apnea: An Evaluation and Comparison of Outcomes at Two Academic Centers

Treatment options for obstructive sleep apnea

Obstructive Sleep Apnoea: A Risk Factor for Hypertension

Contact Info

Product

Resources

About